Clostridium difficile is well recognized as the major, if not are colonized on admission, but for patients whose cultures the only, important cause of infectious diarrhea that develops are initially negative for C. difficile, the risk of acquiring the in patients after hospitalization in the United States, and likely, organism increases in direct proportion to length of hospital in developed countries around the world [1] . The temporal stay. In one study, the rate of acquisition was 13% for patients relation between the onset of C. difficile -associated diarrhea hospitalized 1 -2 weeks, and it increased to 50% for those (CDAD) and prior or concurrent antimicrobial therapy has hospitalized ú4 weeks (figure 1) [4] . In addition, asymptomatic caused confusion regarding the pathogenesis of this disease carriage of C. difficile in healthy neonates is very common, and has led to consideration of this infection as distinct from although rates of carriage decrease markedly during the first other enteric diarrhea syndromes such as salmonellosis or shigyear of life. Carriage rates for neonates vary significantly ellosis. Specifically, the understanding of some clinicians and among different nurseries, and the data suggest that C. difficile infection control practitioners is that C. difficile, which in small is acquired nosocomially in this setting rather than via the numbers is part of the normal intestinal flora, subsequently intestinal flora of the mother. proliferates or overgrows because of suppression of the other Although other reservoirs of C. difficile (including numerous indigenous bowel flora by antimicrobials. Our current underanimal species) likely exist outside hospitals, the incidence of standing of the pathogenesis of CDAD is that C. difficile, like community-acquired CDAD (7.7 cases per 100,000 personvirtually all other enteric pathogens, is acquired exogenously years of observation) is low [5] . Risk per antibiotic exposure and that a variety of clinical outcomes ensue following infecperiod (defined as 42 days) is also low (6.7 cases per 100,000 tion, ranging from asymptomatic colonization to diarrhea to risk exposures) [5] . Although CDAD is rarely diagnosed in the more-severe disease syndromes. The unique aspects of this outpatient setting, there is concern that diagnostic testing may enteric pathogen are its important reservoirs of infection (e.g., not be performed sufficiently in this setting to detect CDAD hospitals and chronic care facilities) and its nearly complete and that diagnostic efforts may not be focused on the proper dependence on prior disruption of the ''infection resistance'' patients -i.e., those receiving antimicrobials. In Australia, provided by the indigenous microflora of the intestine, which Riley and colleagues [6] found that the rate of detection of occurs when antimicrobial therapy is administered.
C. difficile in submitted specimens increased from 2.6% to 10.7% after an educational program was instituted to encourage general practitioners to include testing for C. difficile when Epidemiology of CDAD outpatients presented with diarrhea. Similar data for the outpaIn the setting of endemic or epidemic CDAD, surveillance tient setting in the United States are lacking at a time when cultures performed for all patients on the affected hospital the use of antimicrobials in this setting is increasing. ward(s) will identify asymptomatic C. difficile fecal excretors Antimicrobial therapy was associated with the development or carriers [2, 3] . In fact, asymptomatic carriers usually outof pseudomembranous colitis even before C. difficile was recnumber symptomatic patients by several fold, as is the case ognized as the etiologic agent, and this association between with other enteric diseases such as cholera. While colonization antimicrobial agents and C. difficile disease remains nearly of healthy, nonhospitalized adults by C. difficile is uncommon, universal. Although the disease is a toxin-mediated bacterial the rate of colonization among hospitalized adults is often infection, almost all affected patients have recently been treated §20% for those hospitalized ú1 week. Some of these patients with antimicrobials or, occasionally, chemotherapeutic agents for cancer. Clindamycin, ampicillin, and cephalosporins have been most frequently associated with the development of pseudomembranous colitis, whereas parenteral aminoglycosides, (fecal excretors) with metronidazole was no different than that with placebo, and the lack of effect was attributed to the low or nonexistent fecal drug concentrations achieved with metronidazole in these patients who did not have diarrhea. Treatment with vancomycin was temporarily effective (during and immediately after treatment); however, asymptomatic fecal excretors given vancomycin were significantly more likely to have positive stool cultures at the end of a 70-day follow-up period than those given placebo despite the fact that fecal drug concentrations of §1,000 mg/g of stool were achieved during treatment.
We interpret this to be a result of ongoing exposure to C. difficile and of increased susceptibility to C. difficile infection because of bowel flora disruption following vancomycin treatment. that asymptomatic carriers were at increased risk [2] . Data from swab cultures [4] . Only three (1%) of 323 patients whose hospital four similar longitudinal studies that included 618 noncolostays were õ1 week acquired C. difficile, whereas 10 (50%) of 20 patients hospitalized for ú4 weeks became stool culture positive.
nized patients who were followed up for 1,066 weeks and 192 colonized patients who were followed up for 282 weeks showed that colonized patients were actually at decreased risk of subsequent CDAD [10] . In that analysis colonization was defined as most frequently and appear more prone to result in this complication than other broad-spectrum agents such as ticarcillin/ primary asymptomatic colonization to differentiate patients with this condition from those who may have been culture clavulanate [8] . The mechanism of this difference in risk of CDAD is not known.
positive after resolution of CDAD -a group in which the recurrence of diarrhea is common. Many of the patients with Patients treated with clindamycin are uniquely predisposed to developing CDAD, as demonstrated by a large hospital outprimary asymptomatic colonization were colonized with nontoxigenic strains, but 56% were colonized with virulent, toxibreak in which removal of this agent from the hospital formulary was the single intervention responsible for stopping the genic strains, and nine of the 12 specific types of C. difficile responsible for CDAD in other patients were found in the outbreak [9] . Clindamycin has marked activity against anaerobic bacteria, and in the hamster model (and likely in humans asymptomatically colonized group. As a result, we have derived an alternative model of pathoas well), it has effects on the colonic flora that persist long after treatment is stopped. Clindamycin resistance was a marker genesis for infection with C. difficile ( figure 2B ). We hypothesize that a patient is admitted to a hospital and is at negligible for C. difficile strains implicated in two reported epidemics [9] . One-third of the patients in the original report of clindamycinrisk for CDAD until an antimicrobial agent is administered. If during or after treatment such a patient is subsequently exposed associated pseudomembranous colitis developed symptoms after clindamycin therapy was discontinued [9] ; this finding to C. difficile, the patient either develops CDAD after a short incubation period of a few days or becomes colonized without was difficult to explain initially, but in retrospect likely reflected both the prolonged effect of clindamycin on the indigediarrhea, or, potentially, does not become infected at all. Our data from the four longitudinal studies indicate that once estabnous bowel flora after treatment was stopped and the continued intermittent exposure of these hospitalized patients to C. diffilished as an asymptomatic carrier, a patient is at decreased risk for CDAD. Patients appear to be continually at risk of exposure cile.
With the recognition of hospitalization and antimicrobial to C. difficile throughout hospitalization (figure 1) and become vulnerable to infection only after they have been exposed to therapy as major risk factors for CDAD, as well as the high prevalence of asymptomatic C. difficile carriers present in hosantimicrobials. Thus, CDAD can be viewed as at least a ''three-hit'' disease pital wards, it seems intuitive to hypothesize that these colonized patients are at increased risk for CDAD, particularly [12] . Two components appear to be essential: first, exposure to antimicrobials, and second, exposure to toxigenic C. difficile. when they are exposed to antimicrobial therapy (figure 2A). If this hypothesis is true, such asymptomatic carriers would be Prospective observations suggest that the majority of patients do not become ill following the first two ''hits.'' The presence potential targets for infection control interventions to prevent CDAD. Eradication of C. difficile colonization has been atof at least one additional factor appears to be necessary for CDAD to occur. The additional factor may be related to host tempted in the past and has been studied in a controlled fashion [11] . The outcome after treatment of asymptomatic carriers susceptibility or immunity, to the virulence of the particular / 9c4c$$my10 04-09-98 23:49:05 cida UC: CID Figure 2 . A, Initial hypothesis of Clostridium difficile acquisition and pathogenesis of C. difficile -associated diarrhea (CDAD). In this scenario, a patient acquires C. difficile after some period of hospitalization and is subsequently at risk for CDAD when exposed to antimicrobial therapy. B, Revised hypothesis of C. difficile acquisition and pathogenesis of CDAD. In this scenario, a hospitalized patient is intermittently exposed to C. difficile throughout his/her hospitalization but does not become highly susceptible to C. difficile infection until after receiving antimicrobial therapy. After a very brief incubation period following infection, the clinical outcome is determined. Recent data support this hypothesis and indicate that once asymptomatic colonization is established, a patient is at subsequent decreased risk of CDAD [11] .
C. difficile strain, or to the type and timing of antimicrobial was endemic but the rate of CDAD was not high, 19 distinct HindIII REA types were both introduced and acquired on a exposure. However, it is clear from molecular typing studies that even the most virulent of C. difficile strains produces single ward by different patients [4] . Nosocomial acquisition of a strain was preceded by documented introduction of that asymptomatic colonization more often than CDAD, and this finding suggests that factors in addition to virulence are necesstrain into the ward by an asymptomatic carrier in 16 (84%) of 19 instances; this finding implicated asymptomatic carriers sary for CDAD to occur [2] .
Even if patients asymptomatically colonized with C. difficile as the source of infection for other patients and suggested that most C. difficile infections are nosocomially acquired, even are not at increased risk of CDAD, it has previously been reported that elderly patients asymptomatically colonized with in settings of endemicity, where multiple different strains are present. C. difficile are at increased risk of developing protein-losing enteropathy [13] . However, a subsequent prospective study, Outbreaks of CDAD, often due to a unique strain or a closely related group of C. difficile strains, continue to be reported. The did not show that protein-losing enteropathy was a subclinical manifestation of asymptomatic C. difficile colonization but did causes of these outbreaks are often unclear and are potentially related to problems with infection control, antimicrobial use confirm the presence of protein-losing enteropathy in patients with CDAD as well as those with diarrhea not caused by patterns, or increased virulence of particular strains. Recently, large outbreaks of CDAD in three widely separated geographic C. difficile [14] .
Outbreaks of diarrhea due to a specific strain or type of locations in the United States have been shown to be caused by the same strain [16] . Preliminary findings of an international C. difficile have frequently been reported in hospitals: 79% of strains that caused a large outbreak in the United Kingdom collaborative typing study also suggest that some strains may be disseminated across different countries and continents [17] . were of one indistinguishable cluster, as determined by pyrolysis mass spectrometry [7] . However, even in the setting of an outbreak caused by one unique strain, multiple different strains Control and Prevention are usually present in the background. Discriminating genotyping systems for C. difficile, such as restriction endonuclease
The rapidity with which vancomycin-resistant enterococci (VRE) have spread in health care facilities is indicative of the analysis (REA), pulse-field gel electrophoresis, and arbitraryprimed PCR, have demonstrated a remarkable heterogeneity of difficulty in preventing and controlling the spread of C. difficile in these same institutions. Both of these nosocomial problems strains, even within the same institution or ward during the same period [4, 15] . More than 400 unique types of C. difficile, are characterized by similar epidemiological characteristics, including asymptomatic gastrointestinal carriage, contaminaorganized into 96 distinct toxin-negative or toxin-positive groups, have now been identified by HindIII REA, suggesting tion of the environment, and contamination of the hands of personnel. Similarly, the risks of infection with either organism that the organism is highly diverse.
The presence of a variety of C. difficile strains in the same are increased in association with increased length of hospitalization; advanced age; severity of underlying illness; prior use hospital setting and among different patients with little obvious epidemiological linkage has been interpreted by some investiof antimicrobials, including third-generation cephalosporins; use of electronic rectal thermometers; and use of enteral feedgators as evidence that C. difficile infections result from endogenous carriage of the organism. In one setting where C. used for infections caused by both VRE and C. difficile; these testing of stool for C. difficile cytotoxin should be done only for hospitalized adults with both prior antimicrobial use (within strategies include barrier-isolation precautions of various types to prevent horizontal transmission of the organism and controls 30 days) and one or both of the following symptoms: significant diarrhea (at least three watery or unformed stools in 24 hours) on the use of certain antimicrobials to reduce the risk of colonization and infection. Unfortunately, it is difficult to ensure or abdominal pain [21, 22] . The major benefit of this rule is that it has a very high negative predictive value (94% -97%) compliance with these types of recommendations, a factor that may explain the limited success of control and prevention meafor patients who do not meet the criteria for testing, which would negate or defer the need for 29% -39% of the cytotoxin sures to date.
Two sets of guidelines for the prevention and control of tests ordered. Testing can still be performed later for the few patients whose CDAD is not diagnosed by using this strategy C. difficile infection have been published [19, 20] . The guidelines from the American College of Gastroenterology (ACG) if their symptoms persist or worsen. and the Society for Healthcare Epidemiology of American
The fundamental issue of the lack of a single laboratory test (SHEA) are summarized and compared in table 1. These guidethat is both sensitive and specific for diagnosing CDAD relines differ substantively only in the inclusion of a disinfection mains unresolved and has been summarized in prior reviews product recommendation and education recommendation from [19, 20, 23] . The most specific test, the cell cytotoxin assay, the ACG and a recommendation regarding replacement of elecand the most sensitive test, stool culture for C. difficile, are tronic thermometers from SHEA. Justification for and strength both associated with relatively slow turnaround times; both of the recommendations is provided in the SHEA document, require a minimum of 2 days to yield results. Even in laboraand the ACG guidelines provide a detailed discussion of infectories where both of these tests are performed to obtain maximal tion control issues. Other preventive strategies are under evalusensitivity and specificity, results cannot be obtained rapidly. ation, including induction of passive immunity by oral adminisMore rapid tests (those requiring 2 -4 hours to perform), such tration of C. difficile antibodies, use of vaccines against as the EIA for detecting toxin A or toxins A and B, are very C. difficile or its toxins, and development of biological interferspecific but somewhat less sensitive than the cell cytotoxin ence methods of various types.
assay, and if these tests are batched and not run daily in the laboratory, the results may not be reported faster. Tests that detect only toxin A may miss a small but increasingly reported Diagnosis and Treatment number of C. difficile isolates that produce toxin B but not toxin A [24] . The most rapid test, latex agglutination, which An optimal laboratory test for CDAD remains to be develtests for the presence of glutamate dehydrogenase (not toxin), oped, although progress has been made on the question of is neither sensitive nor specific, and like culture, does not distinclinical selection of patients to be tested for CDAD. A rule for guish toxigenic from nontoxigenic C. difficile [25] . laboratory testing of hospitalized patients for CDAD (defined Practice recommendations regarding the diagnosis of CDAD in the laboratory as a positive cell cytotoxin assay) has been derived and validated in the clinical setting. This rule is that from the two published sets of guidelines emphasize different / 9c4c$$my10 04-09-98 23:49:05 cida UC: CID testing of these patients is discouraged. 4. Endoscopy is reserved for special situations, such as when a rapid diagnosis 4. Stool culture is the most sensitive test for CDAD, whereas the is needed and test results are delayed or the test is not highly sensitive, or stool cell cytotoxicity assay (toxin B) is the most specific; for the patient has ileus and a stool sample is not available, or when other maximal diagnostic sensitivity and specificity, performance of colonic diseases are included in the differential diagnosis.
both tests is recommended. 5. EIAs for toxin A are rapid but may be less sensitive or less specific than cell cytotoxin assays; use of EIA in place of cytotoxin assay is recommended as an acceptable alternative to the cell cytotoxin assay. 6. The latex agglutination test detects glutamate dehydrogenase and is not as sensitive as culture, cell cytotoxin, or enzyme immunoassay tests; its use is discouraged.
* Data are from [20] . † Data are from [19] .
aspects of diagnosis (table 2) . As the basis for suspecting a of positivity in cytotoxin-negative stools (30% -39%) [27 -29] ; thus, in our opinion, these tests are not sufficiently sensitive diagnosis of CDAD, the ACG recommendations emphasize a history of antibiotic use within 2 months before the onset of or discriminatory to serve as good screening tools for CDAD. Since neither a positive nor negative result of the fecal leukodiarrhea and the onset of diarrhea §72 hours after hospitalization. The SHEA recommendations emphasize testing only diarcyte test will obviate the need to do specific testing for C. difficile or C. difficile toxin, it seems more efficient to simply rheal stools and advise against testing asymptomatic patients and young children. The latter recommendation against testing bypass the fecal leukocyte test and order a more specific C. difficile toxin assay for patients who have received antibiotchildren with diarrhea for the presence of C. difficile toxin is supported by the results of a clinical trial of the efficacy of ics and develop diarrhea in the hospital. Although most patients will require specific therapy, it toxin B detection for 618 children (median age, 21 months) with diarrhea and 135 controls (median age, 18 months) [26] .
should be remembered that CDAD is a complication of antimicrobial therapy and that discontinuation of the offending agent Toxin was found in 4.2% of specimens, but its presence did not correlate with the diarrheal symptoms in either inpatients may be the only intervention necessary. Diarrhea will resolve without specific antimicrobial therapy in 15% -23% of patients or outpatients.
The remainder of the SHEA and ACG recommendations with CDAD [30, 31] . Metronidazole, vancomycin, teicoplanin, and fusidic acid are all effective therapeutic agents for CDAD, focus on the relative merits of the types of tests available and strategies for testing, including submission of multiple stool but most clinical experience has been with metronidazole and vancomycin. Metronidazole is presently considered the initial specimens; this latter strategy partially overcomes the lack of sensitivity of the cell cytotoxin assay but adds further delay in drug of choice (despite the fact that the U.S. Food and Drug Administration has not approved it for this indication) because making a diagnosis [27] . These latter recommendations result from the current lack of a single rapid, sensitive, and specific of clinical efficacy that is comparable to that of vancomycin [31, 32] , because of lower cost, and because of concern over test and are likely to change when such a test becomes available.
spread of glycopeptide resistance to other pathogens such as enterococci. However, the high degree of intestinal absorption The question of the utility of the test for fecal leukocytes or the stool lactoferrin test in screening for CDAD has been raised.
of metronidazole and the inability to detect it in the stools of treated, asymptomatic patients has caused concern about its The sensitivity (60% -75%) of these tests in studies that have demonstrated the highest percentage of positive tests in cytouse. Bactericidal fecal concentrations of the drug are present in patients with CDAD, but these concentrations decline as the toxin-positive specimens is also accompanied by a high rate / 9c4c$$my10 04-09-98 23:49:05 cida UC: CID diarrhea decreases. Possible explanations for this observation ment of C. difficile colitis as well as other inflammatory or invasive diarrheal syndromes. As is the case with treatment of include the secretion of metronidazole directly through inflamed mucosa during episodes of diarrhea or incomplete abmultiple recurrences, treatment is empirical when the oral route is not reliable. Attempts to achieve effective antimicrobial consorption of the drug during episodes of diarrhea because of rapid intestinal transit time.
centrations at the site of infection have included administration of intravenous metronidazole, administration of vancomycin In addition to two randomized, controlled studies, there has been a study of ú600 patients at one institution who were by either rectal enema or placement of a long catheter in the small intestine, or combinations of these regimens [30] . Finally, treated for CDAD with metronidazole; the drug intolerance rate, treatment failure rate, and relapse rate were 1%, 2%, and surgical intervention is indicated for patients with toxic megacolon who do not respond to medical treatment or for those 6%, respectively [30] . Oral therapy with either metronidazole or vancomycin for 10 days is effective in ú95% of patients with suspected colonic perforation. A variety of procedures have been performed, but subtotal colectomy with sparing of [19] . Therefore, we recommend the following therapeutic regimens, given orally for 10 days: first choice, metronidazole, 250 the distal rectum may be the preferred surgical option [35] . mg four times daily or 500 mg three times daily; alternative choice, vancomycin, 125 mg four times daily [19, 20, 32] . No Summary and Unresolved Problems diagnostic testing at the end of treatment or as follow-up is recommended unless symptoms (almost always diarrhea) recur.
Declining hospital admission rates and shorter hospital stays have resulted in a reduction in the likelihood that patients will Although most patients respond to specific therapy, 5% -30% of patients will develop recurrent CDAD, usually within acquire CDAD, but the increased severity of illness of patients in hospitals and the higher rate of immunosuppression among 1 or 2 weeks after treatment for the original episode has been discontinued [19] . Recurrence of diarrhea may be caused by a these patients has resulted in an increased proportion who are receiving antimicrobials and are thus at increased risk of relapse due to the original organism or reinfection by a new C. difficile organism. Stool testing for CDAD should be per-CDAD. Although a circumstance not well studied in the United States, patients in the community may also be at increasing formed to document recurrence before retreatment is instituted. Diarrheal recurrences are not due to the development of antimirisk of developing CDAD when they are treated with antimicrobials at home; this is an observation that has been made for crobial resistance, and patients typically respond again to the agent used to treat the original episode [30] . A small number of Australian patients but has not been duplicated in other patient populations [6] . patients develop multiple recurrences; they respond to specific therapy each time but develop recurrent symptoms and have It seems clear that three major issues continue to plague physicians and infection control practitioners with respect to positive stool cytotoxin assays after completion of a course of treatment with metronidazole or vancomycin.
the management of CDAD. The first issue is the lack of a rapid, sensitive, and specific test for CDAD; the second is the A variety of empirical approaches have been used to treat patients with CDAD, including biotherapeutic measures; the relative inability to control and prevent CDAD in hospitals and institutions; and the third is the inability to treat patients rationale of such measures is to avoid further antibiotic therapy and allow the normal colonic flora to reestablish itself. They effectively because of the problem of disease recurrence. The availability of more-rapid and more-sensitive diagnostic tests include administration of Saccharomyces boulardii or Lactobacillus species, rectal infusion of feces or a synthetic fecal bactewill enable clinicians to diagnose CDAD more accurately and in a timely fashion. Breakthroughs in this area are likely to rial flora, and the administration of a nontoxigenic C. difficile strain. Additional strategies have involved administration of come through the use of more-sensitive monoclonal antibody test systems that detect both toxin A and toxin B or through vancomycin and rifampin in combination, vancomycin in tapering doses, cholestyramine, and intravenous gamma globulin; the use of PCR with primers from the toxin A and toxin B sequences of C. difficile. whole-bowel irrigation; and withholding of all treatment with careful observation [19] . Our personal preference for the treatThe second issue, CDAD prevention and control, requires new and innovative approaches beyond that of traditional infecment of multiple relapses is the combination of vancomycin plus rifampin for 10 days, as originally described by Buggy et tion control-barrier methods. It may be possible to exert much more influence on the rates of CDAD by focusing on antimicroal. [33] , but no critical comparative data, other than those for the use of S. boulardii (which is not approved for use in the bial use patterns in hospitals. It has certainly been shown with clindamycin that control of the use of this agent can rapidly United States) on the efficacy of treatment of CDAD recurrences are available [34] .
eliminate a CDAD outbreak [9] . It is likely that other antimicrobial agents or groups of agents are similarly closely linked to Toxic megacolon is the most serious manifestation of C. difficile infection and, paradoxically, may present in the CDAD rates and that by use of risk analysis, the role of other antimicrobials such as extended-spectrum cephalosporins may absence of diarrhea. In addition, some cases may be precipitated by the use of antimotility agents such as diphenoxylate be more frequently identified and the use of these agents controlled to successfully lower CDAD rates [36] . Indeed, it beand loperamide. These agents are contraindicated for the treat-/ 9c4c$$my10 04-09-98 23:49:05 cida UC: CID
